Comparison of Combination Therapy of Olmesartan plus Azelnidipine or Hydrochlorothiazide on Renal and Vascular Damage in SHR/NDmcr-cp Rats | Zendy

Hajime Nagasu | Zendy; Minoru Satoh | Zendy; Daisuke Yorimitsu | Zendy; Naruya Tomita | Zendy; Tamaki Sasaki | Zendy; Naoki Kashihara | Zendy

Open Access

Comparison of Combination Therapy of Olmesartan plus Azelnidipine or Hydrochlorothiazide on Renal and Vascular Damage in SHR/NDmcr-cp Rats

Author(s) -

Hajime Nagasu,

Minoru Satoh,

Daisuke Yorimitsu,

Naruya Tomita,

Tamaki Sasaki,

Naoki Kashihara

Publication year - 2011

Publication title -

kidney and blood pressure research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.806

H-Index - 51

eISSN - 1423-0143

pISSN - 1420-4096

DOI - 10.1159/000323535

Subject(s) - olmesartan , hydrochlorothiazide , medicine , pharmacology , combination therapy , oxidative stress , endocrinology , renal function , diuretic , angiotensin ii , kidney , blood pressure , urology

Although the recommended target blood pressure for patients with chronic kidney disease is <130/80 mm Hg, this is difficult to achieve by treatment with an angiotensin receptor blocker alone. Addition of either a calcium channel blocker or a diuretic is suggested as second-line medication; however, which combination is most beneficial for target-organ protection remains unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research